Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China

BACKGROUND: Fruquintinib, a vascular endothelial growth factor receptor inhibitor, is a new anticancer drug independently developed in China to treat refractory metastatic colorectal cancer (mCRC). In Japan, regorafenib combined with nivolumab has been demonstrated to be promising in patients with r...

Descripción completa

Detalles Bibliográficos
Autores principales: Gou, Miaomiao, Qian, Niansong, Zhang, Yong, Yan, Huan, Si, Haiyan, Wang, Zhikuan, Dai, Guanghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300867/
https://www.ncbi.nlm.nih.gov/pubmed/35875064
http://dx.doi.org/10.3389/fonc.2022.851756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300867/
https://www.ncbi.nlm.nih.gov/pubmed/35875064
http://dx.doi.org/10.3389/fonc.2022.851756

Ejemplares similares